Skip to content

Organon OGN Free cash flow

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Biogen logo
BiogenBIIB
$594.3M+167%
AbbVie logo
AbbVieABBV
$3.56B+155%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$34.92M-507%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Calculated from Organon’s reported figures.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's free cash flow?
Organon (OGN) reported free cash flow of $188M in Q1 2026.
How has Organon's free cash flow changed year-over-year?
Organon's free cash flow increased by 337.2% year-over-year, from $43M to $188M.
What is the long-term trend for Organon's free cash flow?
Over 4 years (2021 to 2025), Organon's free cash flow has grown at a -27.8% compound annual growth rate (CAGR), from $1.98B to $538M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.